česky | english


PLEASE NOTE: Data collection for the mCRC part of the Erbitux registry was terminated by the end of 2010. Data on Erbitux administration to mCRC patients are currently being entered into the Corect registry; monitoring of Erbitux administration to head and neck cancer patients was terminated completely.

The ERBITUX project monitors the effectiveness of treatment with the targeted biological therapy Erbitux, which is currently used for the indications of metastatic colorectal cancer and locally advanced squamous cell carcinoma of head and neck. The project belongs to the category of drug registries and is supported by the Board of the Czech Society for Oncology. The project involved two separate registries, as there were two main groups of monitored patients: those with colorectal cancer and those with head and neck carcinoma (see the Electronic case report forms).

Primary objectives of the project:

  • monitoring the overall number of Czech patients treated with Erbitux,
  • assessment of treatment safety,
  • assessment of treatment effectiveness.

Secondary objectives of the project:

  • analysis of patients' survival in relation to monitored clinical factors,
  • analysis of patient cohort treated with Erbitux in relation to Czech reference population data.

Medicinal product Erbitux

Cetuximab (Erbitux®) is a monoclonal IgG1 antibody which specifically binds to the epidermal growth factor receptor (EGFR). Cetuximab is highly specific and has a higher affinity to the receptor than the two main activating growth factors – the epidermal growth factor (EGF) and the transforming growth factor alpha (TGF alpha).

Cetuximab binding to EGFR blocks the ligand-induced EGFR signalling. Consequently, on the cellular level, it inhibits the proliferation, angiogenesis and dedifferentiation; it stimulates the apoptosis and prevents the metastasis formation.

Considering the fact that Erbitux® is a monoclonal IgG1 antibody, its anticancer effect can be potentiated by the antibody-dependent cell-mediated cytotoxicity (ADCC). As a consequence, patients with EGFR-expressing tumours can benefit not only from the receptor inhibition, but also from the immunostimulant effect of cetuximab.

You can learn more information on Erbitux® on the website www.erbitux.com.


  1. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 1975;15:617.
  2. Artega CL. The target epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001+19:32S-40S
  3. Baselga J, Trigo JM, Bourhis J et al. Cetuximab (C 225) plus cisplatin/carboplatin is active in patiens with recurrent/metastatic squamous cell carcinoma of the head and neck progressing on the same dose and schedule platinum-based regimen. Proc ASCO 2002; 21: Abst 925
  4. Betka J. P��ísp��vek ke klasifikaci kr��ních uzlin a blokových direkcí. Otolaryngol 1996: 45 : 73-77
  5. Black RJ, Bray F, Ferlay J et al. Cancer incidence and mortality in the European Union. Cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33 : 1075-1107
  6. Bonner JA, Goraly J,Harari PM et. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck. A phase III study of high dose radiation therapy with and without cetuximab. Proc ASCO 2005; 23: 5507, NEJM 2006; 354: 567
  7. Burtness BA, Li Y, Flood W et al. Phase II randomized trial of cisplatin + placebo versus cisplatin + C255, a monoclonal antibody directed to the EGFR. An Eastern Cooperative Oncology Group Trial. Clin Cancer Res 2003: 9 Suppl: Abst 77
  8. Hájek R, Vorlí��ek J, Slavík M. P��ehled protinádorové aktivity paclitaxelu v klinických studiích. Klin Onkol 1995; 8 : 33 - 44
  9. Henderson MM. International differences in diet and cancer incidence. J Natl Cancer Inst Monogr 1992;599.
  10. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94:1593-1611
  11. Kost��ica R, Smilek P, Hložek J a spol. Sou��asná komplexní lé��ba nádorů hlavy a krku. Lék. Fakulta MU Brno 2003.
  12. Mazánek, J. Nádory orofaciální oblasti. Victoria Publishing, 1997.
  13. Mechl Z, Abrahámová J. Postavení cetuximabu v lé��b�� pokro��ilých nádorů ORL oblasti. Remedia 2006; 16 : 110 - 115
  14. Naramura M, Gilles SD, MendelsohnRA, Mueller BM et al. Therapeutic potential of chimeric a murine anti-( epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 1993;37:343-349
  15. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33.
  16. Pecen , Topol��an O, Koukalová H et al. Epidemiology of colorectal carcinoma in the Czech Republic. J Tumor Marker Oncology, 2000, 15(1), 55:56
  17. Posner M.R. Epidemiology, Outcomes and Conventional Treatment Options for Patiens With Cancers of the Head and Neck. CME, 2006; March 10
  18. Regionální centrum Národního onkologického registru. Zhoubné novotvary, Jižní Morava - rok 1997, p��edb��žné údaje MOU v Brn�� 1998
  19. Shibua J, Mathers CD, Bosch-Pinto C et al. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2002; 2: 37
  20. Smilek P, Kost��ica R, Mechl Z, et al. Maligní nádory hlavy a krku: Diagnostické a lé��ebné postupy u maligních chorob. Z.Adam, J. Vorlí��ek, J.Vaní��ek a kol. edit., Grada 2002
  21. Spurný V, Mechl Z, ��ervená R. Sou��asné možnosti chemoterapie a radioterapie nádorů oblasti hlavy a krku. Praktický léka�� 2002 ; 82 : 541-545
  22. Weber TK, Chin HM, Rodriguez-Bigas M, et al. Novel hMLH1 and hMSH2 germline mutations in African Americans with colorectal cancer. JAMA 1999;281:2316.
  23. Wilmink AB. Overview of the epidemiology of colorectal cancer. Dis Colon Rectum 1997;40:483.